IGM Biosciences Management

Management Kriterienprüfungen 2/4

IGM Biosciences CEO ist Mary Harler , ernannt in Oct 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.59% der Aktien des Unternehmens, im Wert von €2.95M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3 Jahre bzw. 6 Jahre.

Wichtige Informationen

Mary Harler

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.6%
Durchschnittliche Amtszeit des Managements	3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Mary Harler (59 yo)

less than a year

Amtszeit

Ms. Mary Beth Harler, M.D. is the Chief Executive Officer of IGM Biosciences, Inc. since October 01, 2024 and serves as its Director. She had been Head of Research & Autoimmunity at IGM Biosciences, Inc. s...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mary Harler	CEO & Director	less than a year	keine Daten	0.59% € 3.0m
Misbah Tahir	Chief Financial Officer	5.8yrs	US$1.08m	0.035% € 177.5k
TS Harigopal	Senior Vice President of Group Operations	1.8yrs	keine Daten	keine Daten
Steven Weber	Senior VP	2.7yrs	keine Daten	0.0043% € 21.8k
Paul Graffagnino	Senior Vice President of Legal Affairs	3.8yrs	keine Daten	keine Daten
Suzette Tauber	Chief Human Resources Officer	5.4yrs	keine Daten	keine Daten
Angus Sinclair	Executive Vice President of Research	3.3yrs	keine Daten	keine Daten
Lisa Decker	Chief Business Officer	3.7yrs	US$4.92m	0.030% € 152.6k
Marvin Peterson	Executive Vice President of Process Development & Manufacturing	3.6yrs	keine Daten	keine Daten
Elizabeth Haanes	Senior Vice President of Intellectual Property	2.6yrs	keine Daten	keine Daten
Elaine Sapinoso	Senior Vice President of Quality	1.8yrs	keine Daten	keine Daten
Faraz Siddiqui	Senior Vice President of Manufacturing Operations	1.3yrs	keine Daten	keine Daten

3.0yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: 1K0Das Führungsteam des Unternehmens gilt als erfahren (3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mary Harler	CEO & Director	no data	keine Daten	0.59% € 3.0m
Felix Baker	Independent Director	3.8yrs	US$168.55k	0.0037% € 18.8k
M. Behrens	Independent Director	5.8yrs	US$178.30k	0.68% € 3.4m
Mark Davis	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Rafi Ahmed	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Michael Lee	Independent Director	5.3yrs	US$166.09k	0.016% € 79.0k
Jakob Topsoe	Independent Director	6.3yrs	US$166.09k	0.15% € 748.1k
Julie Hambleton	Independent Director	6.3yrs	US$204.09k	0.0034% € 16.9k
Christina Topsoe	Independent Director	6.3yrs	US$175.84k	0.099% € 497.9k
William Strohl	Independent Director	6.3yrs	US$236.59k	0% € 0
Elizabeth Thompson	Independent Director	1.1yrs	US$167.54k	0.0073% € 36.9k
Gordon J. Freeman	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

6.0yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: 1K0Die Vorstandsmitglieder gelten als erfahren (6 Jahre durchschnittliche Amtszeit).

IGM Biosciences Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

CEO, President & Director recently sold €82k worth of stock

Insufficient new directors

IGM Biosciences, Inc. Announces Board Changes

CEO, President & Director recently sold €221k worth of stock

Recent updates

Third quarter 2024 earnings released: US$1.01 loss per share (vs US$1.04 loss in 3Q 2023)

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

Second quarter 2024 earnings released: US$0.79 loss per share (vs US$1.43 loss in 2Q 2023)

IGM Biosciences, Inc. Provides Pipeline Updates

First quarter 2024 earnings released: US$0.83 loss per share (vs US$1.33 loss in 1Q 2023)

IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

CEO, President & Director recently sold €82k worth of stock

Full year 2023 earnings released: US$4.71 loss per share (vs US$5.32 loss in FY 2022)

Insufficient new directors

Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.32 loss in 3Q 2022)

IGM Biosciences, Inc. Announces Board Changes

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

IGM Biosciences, Inc. announced a financing transaction

IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors

IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development

CEO, President & Director recently sold €221k worth of stock

Independent Director recently bought €1.0m worth of stock

Insufficient new directors

Independent Director recently bought €1.0m worth of stock

Independent Chairman of the Board recently bought €145k worth of stock

Insufficient new directors

IGM Biosciences, Inc. Appoints Steven Weber as Principal Accounting Officer

Independent Director recently bought €224k worth of stock

Independent Director recently bought €1.3m worth of stock

IGM Biosciences, Inc. Advances Novel Antibody IGM-6268 into Clinical Trials for the Treatment and Prevention of COVID-19

IGM Biosciences, Inc. Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting

IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19

IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer

New 90-day high: €94.00

Independent Director has left the company

IGM Biosciences, Inc. Announces Board Changes

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Independent Director recently bought €3.3m worth of stock

New 90-day high: €88.50

IGM Biosciences, Inc. Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma

IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting

IGM Biosciences, Inc. Initiates First-In-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’S Lymphoma

AbCellera Biologics Inc. and IGM Biosciences, Inc. Announce Multi-Year Antibody Discovery Collaboration

New 90-day high: €69.50

Independent Director recently bought €1.5m worth of stock

New 90-day low - €41.00

New 90-day low - €45.60

IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from Russell 3000 Value Index

IGM Biosciences, Inc.(NasdaqGS:IGMS) dropped from Russell Microcap Value Index

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter